Latest Modus Therapeutics News & Updates

See the latest news and media coverage for Modus Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Modus Therapeutics

Swedish biotechnology company developing sevuparin

modustx.com
Headquarters
Stockholm, Sweden
Founded year
2011
Company type
Public company
Number of employees
4–10

Last updated

Latest news about Modus Therapeutics

In short: Modus Therapeutics advanced its clinical pipeline for sevuparin, notably in CKD-related anemia, while securing capital through multiple financings.

Company announcements

  • Modus Therapeutics

    Modus announces outcome of TO 2026 warrants exercise

    The exercise rate is 94.8%, yielding approximately SEK 9.5 million before costs and 18% dilution.

  • Modus Therapeutics

    Modus Therapeutics invites shareholders to AGM

    The meeting occurs on May 28, 2026, in Stockholm. Proposals include board elections, no dividend, and share issue authorization.

  • Modus Therapeutics

    Modus Therapeutics publishes annual report for 2025

    The report is available for download on the company’s website. It covers the financial year 2025.

  • Modus Therapeutics

    KDventures subscribes for all its warrants in Modus Therapeutics

    The subscription, worth SEK 5.1 million, represents 51.7% of outstanding warrants at SEK 0.35 per share. CEO welcomes the commitment.

Unlock all announcements with a

Media coverage

  • MFN

    Modus Therapeutics Holding AB: Kallelse till årsstämma i Modus Th...

    Aktieägarna i Modus Therapeutics Holding AB (publ), kallas härmed till årsstämma tisdagen den 20 maj 2025 klockan 11.00 i Advokatfirman Vinges lokaler, Smålandsgatan 20, i...

  • Yahoo Finance

    Interim Report - January-September 2025

    STOCKHOLM – 14 November 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-September 2025. The full report is available on the...

  • PharmaTimes

    Modus Therapeutics advances sevuparin study in chronic kidney disease with anemia - PharmaTimes

    Proof-of-concept phase begins with first patient enrolled...

  • Taiwan News

    Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue

    STOCKHOLM, SWEDEN August 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has raised SEK 28.3 million in...

Unlock all articles with a

Never miss news about Modus Therapeutics

Track Modus Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.